21 October 2020 - - A research team at the National Center for Advancing Translational Sciences (NCATS), an arm of the National Institutes of Health, is working with US-based PerkinElmer, Inc's (NYSE: PKI) AlphaLISA immunoassay to help support the global search for effective COVID-19 therapeutics, the company said.

The NCATS research project is focused on studying small molecule drug compounds that are already approved and in use as treatments but could potentially be repurposed for COVID-19.

The goal of the project is to quickly and reliably identify which small molecule compounds can best disrupt key proteins that bind together to allow for SARS-CoV-2 infection -- the S1 spike protein and the host ACE2 receptor.

Using PerkinElmer's AlphaLISA assay, the NCATS team has been able to efficiently and accurately screen 3,384 molecular entities and narrow them down to a field of 25 quality therapeutic compounds or "hits."

The whole process, from assay development and optimization through screening, has been achieved in just a few months.

The AlphaLISA technology is a homogeneous (no-wash) assay that works by generating a light emission in response to a biomolecular interaction which results in proximity of the bead-binding complex.

The platform can be used to detect and quantitate biomolecules of almost any size in both simple and complex sample types. Its bead-based, luminescent, signal amplification provides increased sensitivity, a wide dynamic range and potential assay miniaturization.

The AlphaLISA technology is part of PerkinElmer's testing and analysis portfolio that helps scientists around the globe fight COVID-19.